Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $163.20 million. The enterprise value is $77.50 million.
Important Dates
The last earnings date was Thursday, March 26, 2026, before market open.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 72.21 million shares outstanding. The number of shares has increased by 0.91% in one year.
| Current Share Class | 72.21M |
| Shares Outstanding | 72.21M |
| Shares Change (YoY) | +0.91% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 9.54% |
| Owned by Institutions (%) | 29.93% |
| Float | 44.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.94 |
| P/TBV Ratio | 2.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.44.
| Current Ratio | 4.07 |
| Quick Ratio | 3.89 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29.32 |
Financial Efficiency
Return on equity (ROE) is -96.20% and return on invested capital (ROIC) is -49.44%.
| Return on Equity (ROE) | -96.20% |
| Return on Assets (ROA) | -42.78% |
| Return on Invested Capital (ROIC) | -49.44% |
| Return on Capital Employed (ROCE) | -133.40% |
| Weighted Average Cost of Capital (WACC) | 6.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.99M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.83% in the last 52 weeks. The beta is 0.21, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +94.83% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 31.15 |
| Average Volume (20 Days) | 910,173 |
Short Selling Information
The latest short interest is 1.03 million, so 1.43% of the outstanding shares have been sold short.
| Short Interest | 1.03M |
| Short Previous Month | 960,875 |
| Short % of Shares Out | 1.43% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 3.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -123.83M |
| Pretax Income | -121.34M |
| Net Income | -121.34M |
| EBITDA | -123.77M |
| EBIT | -123.83M |
| Earnings Per Share (EPS) | -$2.00 |
Full Income Statement Balance Sheet
The company has $116.87 million in cash and $31.16 million in debt, with a net cash position of $85.70 million or $1.19 per share.
| Cash & Cash Equivalents | 116.87M |
| Total Debt | 31.16M |
| Net Cash | 85.70M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 70.43M |
| Book Value Per Share | 1.16 |
| Working Capital | 92.25M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$115.54 million and capital expenditures -$88,000, giving a free cash flow of -$115.63 million.
| Operating Cash Flow | -115.54M |
| Capital Expenditures | -88,000 |
| Depreciation & Amortization | 58,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -115.63M |
| FCF Per Share | -$1.60 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.91% |
| Shareholder Yield | -0.91% |
| Earnings Yield | -74.35% |
| FCF Yield | -70.85% |
Analyst Forecast
The average price target for ABOS is $7.75, which is 242.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.75 |
| Price Target Difference | 242.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |